Antimicrobial Development in the Era of Emerging Resistance

Author(s): Antonio Sorlozano, Cristina Carrasco, Jose Cabeza, Enrique Villegas, Jose Gutierrez

Journal Name: Mini-Reviews in Medicinal Chemistry

Volume 9 , Issue 8 , 2009

Become EABM
Become Reviewer
Call for Editor


Antibiotics currently under study by the Food and Drugs Administration include: faropenem (for treatment of sinusitis, bronchitis, and community-acquired pneumonia), dalbavancin (for catheter infections), telavancin (for treatment of nosocomial pneumonia), oritavancin (for bacteremia), ceftobiprole and iclaprim (for pneumonias). Moreover, all of them would be useful for skin and soft tissue infections.

Keywords: Faropenem, dalbavancin, telavancin, oritavancin, ceftobiprole, iclaprim

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2009
Page: [938 - 955]
Pages: 18
DOI: 10.2174/138955709788681564
Price: $65

Article Metrics

PDF: 7